ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
The role of circulating metallothionein 1 in voriconazole-associated hepatotoxicity.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cuproptosis in spinal cord injury: emerging mechanisms and immunological relevance.Annals of medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Voriconazole-associated liver injury has emerged as a critical factor driving its early discontinuation in clinical practice. However, reliable plasma biomarkers for detecting voriconazole-induced hepatotoxicity remain lacking. Metallothionein 1 (MT1) has been proposed as a potential biomarker for liver injury. This study aimed to investigate the role of circulating MT1 in voriconazole-associated hepatotoxicity. Tandem Mass Tag (TMT) quantitative proteomic analysis was employed to identify potential differential proteins. The circulating MT1 levels were measured in the plasmas of patients undergoing voriconazole therapeutic drug monitoring. TMT quantitative proteomic analysis revealed that MT1 was significantly upregulated in patients with voriconazole-induced liver injury. A total of 252 patients were enrolled in this study. Plasma MT1 levels were positively correlated with the liver function indices alanine aminotransferase (ALT), aspartate aminotransferase (AST), and γ-glutamyl transferase (γ-GT) levels. These levels significantly increased in patients with grade 1 or higher adverse events of ALT, AST, and γ-GT. Additionally, plasma MT1 levels were negatively correlated with procalcitonin and interleukin (IL)-6 levels. Moreover, plasma MT1 levels were negatively correlated with voriconazole trough concentration (C
Indexed as
Identifiers
40996471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.